Novartis gets US clearance for Regulus Therapeutics buyout
Novartis’s acquisition of biopharmaceutical company Regulus Therapeutics has received clearance from the US antitrust authorities. The waiting period under the Hart-Scott-Rodino Act expired on June 20. Novartis’s acquisition of biopharmaceutical company...To view the full article, register now.
Already a subscriber? Click here to view full article